CD33 and acute myeloid leukemia: Pollard et al., in a sub-analysis of the Children’s Oncology Group (COG) Trial AAML0531, investigated the administration of Gemtuzumab Ozogamicin (GO), an anti-CD33 antibody–calicheamicin conjugate, in combination with conventional chemotherapy; 215 pediatric patients with KMT2A-rearranged AML showed an advantage in terms of 5-year OS and 5-year event-free survival (EFS) as a result of receiving GO (63% vs. 53%, and 48% vs. 29%, respectively).